{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:13:14Z","timestamp":1758946394137,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Anthracycline-induced cardiotoxicity has been classified based on its onset into acute, early, and late. It may have a significant burden on the quality and quantity of life of those exposed to this class of medication. Currently, there are several ongoing debates on the role of different measures in the primary prevention of cardiotoxicity in cancer survivors. Our article aims to focus on the role of neurohormonal blockers in the primary prevention of anthracycline-induced cardiotoxicity, whether it is acute, early, or late onset.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Main body of the abstract<\/jats:title>\n<jats:p>PubMed and Google Scholar database were searched for the relevant articles; we reviewed and appraised 15 RCTs, and we found that angiotensin-converting enzyme inhibitors (ACEI) and B-blockers were the most commonly used agents. Angiotensin II receptor blockers (ARBs) and mineralocorticoid receptor antagonists (MRAs) were used in a few other trials. The follow-up period was on the range of 1\u2013156\u2009weeks (mode 26\u2009weeks). Left ventricular ejection fraction (LVEF), left ventricular diameters, and diastolic function were assessed by either echocardiogram or occasionally by cardiac magnetic resonance imaging (MRI). The occurrence of myocardial injury was assessed by troponin I. It was obvious that neurohormonal blockers reduced the occurrence of LVEF and myocardial injury in 14\/15 RCTs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Short conclusion<\/jats:title>\n<jats:p>Beta-blockers, especially carvedilol and ACEI, especially enalapril, should be considered for the primary prevention of acute- and early-onset cardiotoxicity. ARB and MRA are suitable alternatives when patients are intolerant to ACE-I and B-blockers. We recommend further studies to explore and establish the role of neurohormonal blockers in the primary prevention of the acute-, early-, and late-onset cardiotoxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s43044-020-00090-0","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T05:02:54Z","timestamp":1599800574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity"],"prefix":"10.1186","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-8447","authenticated-orcid":false,"given":"Ahmed","family":"Ayuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nik","family":"Abidin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"90_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjh.13399","volume":"170","author":"C Nabhan","year":"2015","unstructured":"Nabhan C, Byrtek M, Rai A et al (2015) Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol 170:85\u201395","journal-title":"Br J Haematol"},{"key":"90_CR2","doi-asserted-by":"crossref","unstructured":"Chihara D, Westin JR, Oki Y et al (2016) Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer","DOI":"10.1002\/cncr.30173"},{"key":"90_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/pbc.20352","volume":"44","author":"MJ Adams","year":"2005","unstructured":"Adams MJ, Lipshultz SE (2005) Pathophysiology of anthracycline- and radiation- associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44:600\u2013606","journal-title":"Pediatr Blood Cancer"},{"key":"90_CR4","first-page":"72","volume":"25","author":"MA Grenier","year":"1998","unstructured":"Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72\u201385","journal-title":"Semin Oncol"},{"key":"90_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adults cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35:893\u2013911","journal-title":"J Clin Oncol"},{"key":"90_CR6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez-Munoz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"90_CR7","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2759\u20132754","journal-title":"Circulation"},{"key":"90_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 61:1355\u20132362","journal-title":"J Am Coll Cardiol"},{"key":"90_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101- Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877","journal-title":"J Clin Oncol"},{"key":"90_CR10","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V et al (2018) Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial. Paediatric Blood Cancer 65:e27308","journal-title":"Paediatric Blood Cancer"},{"key":"90_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859\u20132868","journal-title":"J Am Coll Cardiol"},{"key":"90_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E et al (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Haematol 85:894\u2013896","journal-title":"Am J Haematol"},{"key":"90_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","volume":"69","author":"N Maryam","year":"2017","unstructured":"Maryam N, Ghasem J, Saideh B et al (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69:279\u2013285","journal-title":"J Cardiovasc Pharmacol"},{"key":"90_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","volume":"134","author":"A Tashakori Beheshti","year":"2016","unstructured":"Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G et al (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind, randomized trial. Cardiology 134:47\u201353","journal-title":"Cardiology"},{"key":"90_CR15","doi-asserted-by":"crossref","unstructured":"Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48","DOI":"10.1016\/j.jacc.2006.07.052"},{"key":"90_CR16","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1093\/eurheartj\/ehy566.P6255","volume":"39","author":"AM Abuosa","year":"2018","unstructured":"Abuosa AM, Elsheikh A, Kinsara A et al (2018) Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Eur Heart J 39:6255","journal-title":"Eur Heart J"},{"key":"90_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, Wanderley MRB Jr et al (2018) Carvedilol for the prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71:2281\u20132290","journal-title":"J Am Coll Cardiol"},{"key":"90_CR18","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","volume":"167","author":"MG Kaya","year":"2013","unstructured":"Kaya MG, Ozkan M, Gunebakmaz O et al (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167:2306\u20132310","journal-title":"Int J Cardiol"},{"key":"90_CR19","doi-asserted-by":"crossref","unstructured":"Gulati G, Heck S L, Ree A H et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Eur Heart J 37:1671\u20131680","DOI":"10.1093\/eurheartj\/ehw022"},{"key":"90_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G et al (2010) Protective effect of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160:487","journal-title":"Am Heart J"},{"key":"90_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2014","unstructured":"Akpek M, Ozdogru I, Sahin O et al (2014) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17:81\u201389","journal-title":"Eur J Heart Fail"},{"key":"90_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1254\/jjp.88.183","volume":"88","author":"K Okumura","year":"2002","unstructured":"Okumura K, Jin D, Takai S et al (2002) Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters\u2019. Jpn J Pharmacol 88:183\u2013188","journal-title":"Jpn J Pharmacol"},{"key":"90_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00005344-200009000-00012","volume":"36","author":"T Tokudome","year":"2000","unstructured":"Tokudome T, Mizushigr K, Norma T et al (2000) Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 36:361\u2013368","journal-title":"J Cardiovasc Pharmacol"},{"key":"90_CR24","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474\u20132481","journal-title":"Circulation"},{"key":"90_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","volume":"36","author":"D Cardinale","year":"2000","unstructured":"Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517\u2013522","journal-title":"J Am Coll Cardiol"},{"key":"90_CR26","doi-asserted-by":"crossref","unstructured":"Gulati G, Heck SL, Rosjo H et al (2017) Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac dysfunction during adjuvant Breast Cancer Therapy) study. J Am Heart Assoc 6:e006513","DOI":"10.1161\/JAHA.117.006513"},{"key":"90_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ahj.2006.08.021","volume":"152","author":"AHB Wu","year":"2006","unstructured":"Wu AHB (2006) Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152:828\u2013834","journal-title":"Am Heart J"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-020-00090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-020-00090-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-020-00090-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T23:13:00Z","timestamp":1631315580000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-020-00090-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1186\/s43044-020-00090-0","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, it is a review article; no ethical commit approval is required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}